Phanes Therapeutics announces first patient with colorectal cancer (CRC) dosed in clinical study of spevatamig
SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced that the first patient has been dosed in the clinical study of spevatamig for the treatment...
Covered in this story
What has happened since
- California Resources Corp is down 2.0% since this was published, 8 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on California Resources Corp
- UBS: $53.7 → $68 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $CRC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on California Resources Corp →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.